ERBB2 and colorectal carcinoma: For HER2-positive CRC patients, double anti-HER2 therapy is recommended (Kavuri et al., 2015; Oh & Bang, 2020; Vranic, Beslija & Gatalica, 2021), nevertheless, some patients have disease refractory to treatment.